- Active not recruitingPHASE2
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
This study is looking at a new treatment called botensilimab, sometimes with another drug called balstilimab, for advanced melanoma. It aims to see how well these drugs work, if they are safe, and how the body handles them in people whose melanoma hasn't responded to previous treatments.
For: Advanced MelanomaUnited States · Belgium · Brazil - Ongoing, recruitingTherapeutic exploratory (Phase II)
A MULTICOHORT, OPEN LABEL, PHASE 2 STUDY OF BOTENSILIMAB (AGEN1181) FOR TREATMENT OF ADVANCED MELANOMA REFRACTORY TO PRIOR CHECKPOINT INHIBITOR THERAPY
This study is testing new medicines, botensilimab and balstilimab, for adults with advanced melanoma. These are cancers that have not responded to previous treatments. We want to see if the new medicines can shrink the cancer.
For: Advanced melanoma refractory to prior checkpoint inhibitor therapyBelgium · Germany · Italy - Active not recruitingPHASE1
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
This study is testing a new cancer medicine, botensilimab, sometimes with another drug, balstilimab. It's for people with advanced cancers that haven't responded to other treatments. Doctors want to see if it's safe, how it works, and find the best dose.
For: Advanced Cancer · Angiosarcoma · Colorectal Cancer Without Liver MetastasesUnited States · United Kingdom